Article (Scientific journals)
Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.
Peeters, H.; Louis, Edouard; Baert, F. et al.
2018In Acta Gastro-Enterologica Belgica, 81 (1), p. 15-21
 

Files


Full Text
Efficacity of switching to infliximab in patients...response of adalimumab_AGE_PPA.rtf
Author postprint (2.84 MB)
Download

Acta gastroenterologica is abstracted/indexed in Current Contents, Excerpta Medica, Index medicus, ISI. Published by © Universa Press, Wetteren, Belgium. All rights reserved.


All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adalimumab/therapeutic use; Adult; Aged; Belgium; Crohn Disease/drug therapy; Female; Gastrointestinal Agents/therapeutic use; Humans; Infliximab/therapeutic use; Male; Middle Aged; Prospective Studies; Treatment Outcome; Crohn's disease; adalimumab; infliximab; switching
Abstract :
[en] BACKGROUND AND STUDY AIMS: Anti-TNF monoclonal antibodies are a cornerstone in the treatment of Crohn's disease. Prospective data on switching from the subcutaneous and human adalimumab (ADM) to the intravenous and chimeric infliximab (IFX) are scarce. PATIENTS AND METHODS: In this prospective, observational, multicentre cohort study we included 21 patients with loss of response to ADM despite at least 4 consecutive weekly injections. Clinical response (CDAI drop>/=70 points) and remission (CDAI</=150) were assessed after switching from ADM to IFX after 10 weeks, 6 and 12 months. Predictive factors of response/remission, the need for therapy intensification, discontinuation and safety were investigated. RESULTS: Short-term response and remission (10 weeks) were seen in 57% and 48% respectively. Mid- and long-term clinical response and remission were achieved in 40% and 25% after 6 months and in 45% and 20% after 12 months respectively. At 12 months, 81% still were on IFX. IFX therapy intensification was needed in half of the patients at 6 months and three quarter of patients at 12 months. Undetectable ADM trough levels (despite weekly injections) were a predictive factor for short-term response and remission to IFX. About half of the patients with response at week 10 maintained response at 6 and 12 months. CONCLUSIONS: Switching from ADM to IFX can be efficacious in patients with loss of response, in particular in case of undetectable ADM trough levels. The majority of patients however will need IFX therapy intensification during their first year of treatment.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Peeters, H.
Louis, Edouard  ;  Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Baert, F.
Dewit, O.
Coche, J. C.
Ferrante, M.
Lambrecht, G.
Colard, A.
Van Gossum, A.
Bossuyt, P.
Moreels, T.
Vander Cruyssen, B.
Gils, A.
De Vos, M.
More authors (4 more) Less
Language :
English
Title :
Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.
Publication date :
2018
Journal title :
Acta Gastro-Enterologica Belgica
ISSN :
0001-5644
eISSN :
1784-3227
Publisher :
Acta Medica Belgica, Bruxelles, Belgium
Volume :
81
Issue :
1
Pages :
15-21
Funders :
AbbVie [BE]
Commentary :
(c) Acta Gastro-Enterologica Belgica.
Available on ORBi :
since 02 December 2018

Statistics


Number of views
211 (1 by ULiège)
Number of downloads
95 (0 by ULiège)

Scopus citations®
 
5
Scopus citations®
without self-citations
5

Bibliography


Similar publications



Contact ORBi